<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183440</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0012</org_study_id>
    <nct_id>NCT03183440</nct_id>
  </id_info>
  <brief_title>Efficacy Of Antenatal Maternal Supplementation With GOS/Inulin Prebiotics On Atopic Dermatitis Prevalence In High-Risk One-Year-Old Children</brief_title>
  <acronym>PREGRALL</acronym>
  <official_title>A Multicenter Clinical Trial To Assess The Efficacy Of Antenatal Maternal Supplementation With GOS/Inulin Prebiotics On Atopic Dermatitis Prevalence In High-Risk One-Year-Old Children.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergies are increasing worldwide affecting 30-40% of the population. Among this, Atopic
      Dermatitis (AD) is the earliest and the most common manifestation of allergic diseases
      (prevalence 20%). Recent studies have shown that allergies were associated with a disruption
      of the gut microbial 'balance' suggesting that the use of nutritional intervention very early
      in life may restore an optimal pattern of microflora aiming at improving the host's health.
      So far, most human intervention studies have mainly focused on improving postnatal infant
      colonization. Our study will test the hypothesis that a maternal antenatal prebiotics
      (GOS/inulin) supplementation may be superior to placebo for AD prevention in high-risk
      children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design :

      Inclusion visit at 20 weeks of gestation :

        -  randomization

        -  start of supplementation (GOS/inulin or placebo)

      Phone call at 24 weeks of gestation :

        -  checking tolerance

        -  checking observance

           32 weeks of gestation visit :

        -  replenishment of prebiotics

        -  collect of AE

      Day 1 : assessment of the Transepidermal Waterlos evaluated by a TEWAMETER

      Delivery/per partum Visit

      At M3 : The national recommendations for the dietary diversification of the child will be
      transmitted to the patients

      At M6 : evaluation of AD prevalence by parents

      At M12 : Pediatric dermatology consultation

        -  clinical exam of child

        -  the SCORAD

        -  prevalence of AD

        -  skin prick tests

        -  FDQLI score

        -  assessment of the Transepidermal Waterlos evaluated by a TEWAMETER
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>atopic dermatitis prevalence at M12</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>prevalence will be evaluated according to UK party working group criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>atopic dermatitis prevalence at M6</measure>
    <time_frame>at 6 months of age</time_frame>
    <description>prevalence will be evaluated by a phone questionnaire (ISAAC questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>atopic dermatitis severity</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>evaluated by the SCORAD (Scoring Atopic Dermatitis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of the child and his/her family</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>evaluated by the FDQLI score (Family Dermatitis Quality of life Index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of the prebiotics in mothers</measure>
    <time_frame>from inclusion to delivery</time_frame>
    <description>evaluated by a questionnaire on digestive status (bloating, stomach aches, diarrhea, flatulences,...)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sensitization with the major allergens</measure>
    <time_frame>at 12 months of age</time_frame>
    <description>skin prick tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of the Transepidermal Waterlos</measure>
    <time_frame>at J1 and at 12 months of age</time_frame>
    <description>evaluated by a TEWAMETER(R)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">376</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>PREBIOTICS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>188 pregnant women</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>188 pregnant women</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PREBIOTICS</intervention_name>
    <description>women will daily take a mixture of Galacto-Oligo-Saccharide/inulin (ratio 9:1) from inclusion to delivery</description>
    <arm_group_label>PREBIOTICS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>women will daily take placebo (maltodextrin) from inclusion to delivery</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant women with an eutocic pregnancy before 20 weeks of gestation

          -  women with personal history of atopy diagnosed by a healthcare Professional

          -  Women accepting a complete avoidance of dietary supplements containing prebiotics or
             probiotics during study supplementation

          -  women accepting dermato-pediatric follow-up during the first year of life of the
             new-born (Phone calls at 24 weeks of gestation and 6 months of child and a
             consultation at 12 months of age)

          -  non Tobacco user women

          -  women over 18 years

          -  women without history of gestational diabetes

        Exclusion Criteria:

          -  women not giving up on intake of dietary supplements containing prebiotics or
             probiotics during study supplementation

          -  women refusing dermato-pediatric follow-up during the first year of the newborn

          -  ongoing allergy and/or intolerance to cow's milk proteins

          -  term &gt;21 weeks of gestation
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sebastien BARBAROT, Dr</last_name>
    <phone>(0)240084086</phone>
    <phone_ext>+33</phone_ext>
    <email>sebastien.barbarot@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène AUBERT, Dr</last_name>
    <email>helene.aubert@chu-nantes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume LEGENDRE</last_name>
      <email>guillaume.legendre@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Martine DROUET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne HOPPE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume LEGENDRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHD Vendée</name>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume DUCARME</last_name>
      <email>guillaume.ducarme@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Marion FENOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole POIRAUD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume DUCARME</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent DOCHEZ</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic dermatitis</keyword>
  <keyword>Prevention</keyword>
  <keyword>Prebiotics</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

